KEY POINTS BOX
• Key point 1. The circulating levels of soluble CD14 and lipopolysaccharide-binding protein were higher in patients with primary sclerosing cholangitis compared with healthy controls.
• Key point 2. High levels of the same markers were associated with shorter liver transplantation-free survival in the PSC patients, independent from Mayo risk score. 
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease affecting intraand extrahepatic bile ducts, eventually progressing to end-stage liver disease. 1 There is currently no medical treatment available. In a recent large international cohort study, median liver transplantation-free survival was 14.5 years, 2 while it was 21.3 years in an Dutch population-based study. 3 A feared complication is hepatobiliary malignancy, occurring in 10% of the patients. 2 Approximately 70% of the PSC patients are diagnosed with concomitant inflammatory bowel disease (IBD), predominantly affecting the colon. 1 The close relationship with IBD is the basis of several important hypotheses of PSC pathogenesis. Recent studies have identified an altered gut microbiota in PSC patients, both in stool and the mucosa. 4 It has previously been hypothesized that leakage of bacterial products across an impaired mucosal barrier in the gut could contribute to the disease. The liver is continuously exposed to a large variety of substances, including nutrients, gut bacteria and bacterial products originating from the gut via the portal circulation. Disruption of the mucosal gut barrier, during e.g. alcohol consumption, 5 inflammation or infection, 6 can lead to increased hepatic exposure to a range of bacterial byproducts and metabolites which in turn can activate the immune system and trigger inflammation both systemically and in the liver. 7 Changes in the gut microbiota have also been associated with increased gut permeability, 8, 9 As a proof-of-principle, induction of small intestinal bacterial overgrowth in a rat model has been shown to increase translocation of bacterial products and lead to pathological changes similar to those seen in human PSC. 10 In human PSC, however, intestinal permeability has only been measured in one small study, and no alterations were observed. 11 The classical marker of bacterial translocation is lipopolysaccharide (LPS), which are glycolipids derived from the outer membrane of gram negative bacteria functioning as pathogen associated molecular patterns, eliciting strong immune responses. 12 LPS-binding protein (LBP) is an acute phase protein that binds to and correlates with LPS, 13 and facilitates the association between LPS and soluble CD14 (sCD14). Furthermore, sCD14 mediates the interaction of LPS with cells, thereby signaling the presence of gram-negative bacteria. 14 The concentration of sCD14 thus represents a host response to translocation measure, mainly related to monocyte activation. Zonulin is the only known physiological regulator of intercellular tight junctions and has been shown to correlate with intestinal permeability and could thus be used as a measurement of impaired gut barrier function. 15 Patients with inflammatory diseases like celiac disease and type 1 diabetes also show increased serum levels of zonulin compared to controls. 15 Finally, intestinal fatty acid binding protein (IFABP) is a biomarker for intestinal epithelial cell damage both in vivo and in vitro. 16 Only limited data and non-conclusive studies are available about some of these markers in PSC. 17, 18 Based on the observations described above, we hypothesized that circulating markers of gut barrier function are elevated in PSC compared with controls and that high levels of the same markers are associated with reduced liver transplantation-free survival.
PATIENTS AND METHODS

Patient population and data collection
Diagnosis of PSC was based on typical findings on magnetic resonance cholangiography or endoscopic retrograde cholangiography (ERCP) according to established criteria. 1 Patients were recruited at admission to Oslo University Hospital Rikshospitalet in the period 2008 to 2015. Serum and plasma were collected according to a standardized protocol and stored at -80 degrees until analysis. The time of the first diagnostic cholangiogram defined the time of diagnosis. Duration of disease was defined as the time from diagnosis to serum sampling. Some patients had serum sampled before final diagnosis (i.e. negative disease duration).
Clinical and demographic information was acquired from patient records and research databases regarding clinical and laboratory data, including ascites, encephalopathy, variceal bleeding, type of inflammatory bowel disease, colorectal or hepatobiliary malignancy, and medication at the time of serum extraction. Inflammatory bowel disease was diagnosed based on endoscopy and histological findings, according to accepted criteria. 19 Healthy controls (n=100) were included from the Norwegian Bone Marrow Donor Registry, as used in previous studies. 20 IBD patients with a final diagnosis of ulcerative colitis but without PSC (n=40), were included from the Inflammatory Bowel Disease in South-Eastern Norway (IBSEN) population-based inception cohort. Serum was sampled at the 10-year follow-up. 20 Written informed consent was obtained from each study participant. The Regional Committee for Medical and Health Research Ethics of South-Eastern Norway approved the study (Reference: 2015/2140/REK). The study was carried out in accordance with the Declaration of Helsinki.
Analysis of markers of bacterial translocation and clinical biochemistry
Child-Pugh score, Model for End-Stage Liver Disease (MELD) score and revised Mayo risk score were calculated according to established algorithms. [21] [22] [23] Since only data on presence/absence (and not severity) of ascites/ hepatic encephalopathy were available, only one additional point was given for ascites or hepatic encephalopathy when calculating the 
Statistical analyses
Data are presented as median (range) unless stated otherwise. The Mann-Whitney U test was applied for continuous variables. Correlation between levels of gut leakage markers zonulin, IFABP, sCD14, LBP and LPS were performed by the Spearman's rank correlation test (rho).
Kaplan-Meier plots and log-rank tests were used for survival analyses. The biomarkers of interest were categorized as high and low levels by the median (2 ntiles-option in SPSS).
Receiver operating characteristics (ROC) curve analyses were performed to define area under the curve (AUC), sensitivity and specificity, as well as the optimal cut-offs using Youden's index. When analyzing subgroups, the samples were re-categorized in each stratum. Clinical features and laboratory data from the time of sampling was compared with mortality or liver transplantation with Cox proportional hazards analysis. Statistical analyses were performed using SPSS (version 24; SPSS, Inc., Chicago, IL) and MedCalc (MedCalc Software, Ostend, Belgium). P-values <0.05 were considered statistically significant.
RESULTS
Population characteristics
In total 166 PSC patients (80% male, 73% with IBD) and 100 healthy controls (59% male) were included, with a median age of 41.0 (16.3-72.4) years in the PSC patient group and 39.9 (28.1-56.1) in the control group (Table 1) 
Increased sCD14 and LBP concentrations in PSC patients compared with controls
The concentration of sCD14 was higher in the PSC patients compared to controls, median 1657 (885-4095) and 1196 (835-1776) ng/ml, P<0.001, respectively ( Figure 1A ). LBP was also higher in PSC patients than controls (13662 (4856-34311) vs. 12339 (4674-43400) ng/ml, (P=0.010), Figure 1B ), while zonulin was lower in the patients (32 (6-58) vs. 34 (14-55) ng/ml, (P=0.008), Figure 1C ). IFABP and LPS were similar in PSC patients and controls (P=0.20, Figure 1D and P=0.84, Figure 1E , respectively). There was a modest but significant correlation between sCD14 and LBP in PSC patients (rho=0.22, P=0.005, Figure 1F ), but not in healthy controls (rho=-0.07, P=0.46). Similarly, sCD14 and LPS were correlated in PSC patients (rho=0.23, P=0.003), but not in healthy controls (rho=0.03, P=0.78). There were no significant differences in levels of gut leakage markers between PSC patients with and without IBD, but IBD without PSC had lower levels of sCD14 than PSC patients (Figure 2A and B). PSC patients using ursodeoxycholic acid (UDCA) showed higher levels of sCD14 compared to other PSC patients (1848 (973-3264) vs 1540 (885-4095), P=0.005). Patients on prednisolon or 5-aminosalicylic acid treatment showed similar levels of sCD14 as other patients (data not shown). In order to evaluate the predictive value of sCD14 and LBP, the patients were stratified into high and low concentration by the median and analyzed by Kaplan-Meier plots and log rank tests. Patients with high sCD14 or high LBP concentrations showed reduced liver transplantation-free survival compared with the low concentrations groups (P<0.001 and P=0.043, respectively). There were no significant effects on survival for LPS, zonulin or IFABP (data not shown). ROC tests were subsequently performed to define the optimal cutoffs in the complete PSC population. The AUC of sCD14 to differentiate patients with and without end-point was 0.76 with an optimal cut-off of >1638 ng/ml, associated with a sensitivity of 74% and specificity of 70% ( Figure 3A ). LBP yielded an AUC of 0.59, with the optimal cut-off >13942 ng/ml (sensitivity of 55% and specificity of 64%, Figure 3B ). Using the optimal cut-offs, sCD14>1638 ng/ml was associated with reduced liver transplantationfree survival, mean 3.5 years (CI 2.7-4.2) vs. 6.8 (6.2-7.4), P<0.001, while LBP>13942 ng/ml was associated with a mean survival of 4.3 years (3.4-5.1) vs. 5.8 (5.1-6.5), P=0.005 ( Figure   3C and 3D).
High sCD14 and LBP predict reduced liver transplantation-free outcome
Concentration of sCD14 was higher in the groups with hepatobiliary cancer
Of the 166 PSC patients, 25 had a diagnosis of hepatobiliary malignancy at baseline, or were diagnosed during follow-up (22 of them had cholangiocarcinoma (CC) and 3 had gallbladder cancer (GBC)). The concentration of sCD14 was higher in the cancer groups than in PSC patients without cancer and healthy controls ( Figure 4A ), while there were no significant differences for the other markers. When stratifying according to the occurrence of cancer or not, there was still a strong association between high sCD14 and reduced liver transplantation-free survival in the group without cancer ( Figure 4B ).
Zonulin concentration is confounded by liver synthesis function
Zonulin (encoded by the Haptoglobin gene) is primarily synthesized in the liver. Zonulin Figure 5D and 5E), suggesting that the strongest predictive power is in less advanced disease.
Relationship between cholangitis, cholestasis and gut leakage markers
In PSC, the presence of acute cholangitis may nonspecifically confound the investigated markers. C-reactive protein (CRP) correlated with sCD14 (rho=0.47, P<0.001), LPS (rho=0.22, P=0.007) and leukocytes (rho=0.20, P=0.015). Considering an arbitrary cut-off of CRP>10 mg/L, n=40 (26%) of the patients had elevated and n=112 (74%) normal CRP (n=8 missing values). Elevated CRP was associated with reduced liver transplantation-free survival (log rank P<0.001), however, elevated sCD14 was still associated with decreased survival when patients with high CRP were excluded ( Figure 6A) .
A moderate to strong correlation was observed between cholestasis markers and sCD14, demonstrated for alkaline phosphatase (rho 0.58, P <0.0001) and bilirubin (rho 0.63, P<0.0001), while only a weak correlation was seen between LBP and bilirubin (rho 0.17, P<0.038), Figure 6B -D.
No relationship with genetic variation in the CD14 gene
Other possible confounders are genetic determinants of sCD14 expression. In a previous study in PSC patients, genetic variation in the rs2569190 single-nucleotide polymorphism in the CD14 gene correlated with sCD14 concentration. 18 However, when using genotype data of rs2569190 available from 72 of the included PSC patients from a previous study, 24 there was no relationship between rs2569190 genotype and circulating sCD14 concentration in the present cohort, irrespective of genetic model (genotype or dominant/recessive, data not shown).
Independent effects of sCD14 and LBP in multivariable Cox regression
Cox regression was performed to assess the relationship between sCD14, LBP and established risk factors in PSC. We found both elevated sCD14 and LBP to be associated with reduced liver transplantation-free survival in PSC, independent of Mayo risk score (which entail age, albumin, bilirubin and AST), the presence of reduced synthesis function (elevated INR) or a cancer phenotype (occurrence of hepatobiliary cancer), while elevated CRP was not significantly associated with survival in multivariable models ( Table 2) .
DISCUSSION
In this cross-sectional study of circulating markers related to bacterial translocation, intestinal permeability and monocyte activation, sCD14 and LBP were elevated in PSC patients compared with controls. High levels of sCD14 and LBP were associated with reduced liver transplantation-free survival, suggesting that bacterial translocation may be relevant for disease progression in PSC. Of note, elevated sCD14 was associated with reduced survival even when excluding individuals that were later diagnosed with hepatobiliary cancer, which was associated with the highest sCD14 levels.
Serum concentrations of both sCD14 and LBP were clearly elevated in PSC patients. To our knowledge, there are no previous reports comparing circulating sCD14 and LBP in PSC or other cholestatic diseases with healthy controls. In non-alcoholic fatty liver disease, elevated levels of sCD14 were observed in a study of 113 patients and 21 matched healthy controls, positively correlating with both liver inflammation grade and hepatic sCD14 expression. 25 Elevated sCD14 has also been reported in systemic inflammatory diseases like arthritis 26 and atopic dermatitis. 27 The correlations between sCD14 and LBP, and sCD14 and LPS, suggest that translocation of gut microbial products may in part influence sCD14 concentrations, despite no increase of LPS observed in the systemic circulation. Importantly, sCD14 has been found to be elevated in bile in PSC compared with control subjects undergoing ERCP, 20 indicating that a biliary source of sCD14 is possible. LPS has been reported to accumulate in the biliary epithelium of PSC patients, which also shows hyper-responsiveness to LPS stimulation. [28] [29] [30] One could therefore speculate that there is an increase in LPS in portal blood, which is no longer detectable after first passage of the liver.
High sCD14 and LBP were associated with liver transplantation-free survival independent of Mayo risk score. This is in line with a study of 136 Japanese patients with primary biliary cholangitis (PBC) followed for 8.8 years, where elevated sCD14 at baseline was significantly associated with both liver decompensation and liver-related death or liver transplantation. 31 In contrast to our findings, a recent German study in PSC showed increasing sCD14 associated with reduced risk of liver transplantation or death. 18 The sCD14 concentrations in that study correlated with a common genetic variant of CD14; CD14 -260C>T (rs2569190). A similar correlation was not reproduced in the present study, suggesting that there were major differences between the cohorts. The positive correlations between sCD14, LBP and LPS suggest that sCD14 concentrations in our patient cohort, at least in part, are driven by proinflammatory stimuli and not host genes. These results are also coherent with the association between LBP and reduced liver transplantation-free survival. The German study excluded patients with advanced disease or acquiring cancer, contributing to the differences between the cohorts. 18 Still, the contradictory observations regarding sCD14 and liver transplantationfree survival are difficult to fully explain and warrant further studies.
A critical question when evaluating markers of bacterial translocation in PSC is the disease stage, since cirrhosis per se influences the gut barrier, 32 as well as confounding factors like acute cholangitis and cholestasis. Structural and functional alterations of the gut mucosa that lead to increased intestinal permeability have been described in liver cirrhosis 33 and increased intestinal permeability has been linked to the progression of liver disease and the complications of cirrhosis. 34 In the present study, neither sCD14 nor LBP were affected by the presence of reduced liver synthesis function, as measured by INR. However, reduced liver synthesis function may explain the reduced concentration of zonulin, which is only synthesized in the liver. In contrast, sCD14 was highly elevated and lost predictive power in patients with advanced chronic liver disease as evaluated by Child-Pugh score and MELD, suggesting that the effects of cirrhosis and portal hypertension outweigh any early gut barrier dysfunction. We are uncertain why the use of UDCA was associated with higher sCD14 concentration. UDCA is of limited use in Norway and one possibility is that it is given mainly to symptomatic patients, who could have higher disease activity.
LBP and sCD14 both correlated with CRP, which is in line with elevated levels observed during acute cholangitis. 35 Elevated sCD14 and LBP concentrations have also been observed in patients with distal obstructive jaundice. 36 The correlations observed in particular between sCD14 and alkaline phosphatase as well as bilirubin could therefore suggest that cholestasis per se increases sCD14, although an alternative cause could be the mechanisms driving cholestasis. The elevated sCD14 levels in PSC, irrespective of concomitant IBD, compared with IBD patients without PSC may also point to the liver as an important driving force.
Given the similar concentrations of LPS, IFABP and zonulin (in the group with normal synthesis) in the patients compared with controls, one should therefore be careful before concluding that increased bacterial translocation is the only or major explanatory factor for the present observations. This is in line with the lack of changes in small-bowel intestinal permeability observed in the only permeability study so far published in PSC, 11 although one could argue its relevance given that PSC patients most often experience colonic IBD.
However, sCD14 and LBP were similar in PSC patients with and without a diagnosis of IBD, suggesting either that IBD is less relevant, or that an undiagnosed subclinical inflammatory intestinal process is ongoing also in PSC patients without IBD. Of note, the by far highest concentrations of sCD14 were observed in patients with hepatobiliary cancer. It could be speculated that this is partly related to activated tumor associated macrophages, and serves as rationale for further studies related to sCD14 or other macrophage-related markers in the pathogenesis or as clinical biomarkers in cholangiocarcinoma.
Some limitations should be discussed. The cohort is fairly large, but the results are not independently validated. Missing data for some confounders reduced the number of included patients in the multivariable model. All patients have been included at a tertiary referral center, suggesting that the cohort may represent PSC phenotypes at the severe part of the disease spectrum. All assays were tested and found reproducible in our lab, but may have limitations; e.g. IFABP may be more useful in acute damage and LPS has a short half-life and variability in detection rates. 32 The extensive work to identify an assay not influenced by bilirubin is however a strength of the present study.
In conclusion, sCD14 and LBP were elevated in PSC patients compared with controls. These markers were moderately correlated, and high concentrations were associated with reduced liver transplantation-free survival independent from Mayo risk score, the occurrence of hepatobiliary cancer and reduced synthesis function. This opens the possibility that bacterial translocation may be relevant for disease progression in PSC. associated with a sensitivity of 55% and specificity of 64%. These cut-offs were then used to analyze liver transplantation free-survival in PSC patients stratified by (C) high and low sCD14 (divided by cut-off from the ROC curve test above) and (D) by high and low LBP (divided by cut-off from the ROC curve test above). Data missing for sCD14 in n = 1. 
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